Search

Displaying results 1671 - 1680 of 7540 in total
  1. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred … in pregnancy due to a perceived lower risk of teratogenic effects.

  2. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    It differs from TCAs in that it does not appear to block serotonin reuptake. … Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity.

    Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    pancreatic cells that the body is no longer able to produce insulin on its own. … [A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by

  4. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.

  5. Drug

    Clodronic acid

    go.drugbank.com/drugs/DB00720
    ApprovedInvestigationalVet approved

    [A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910] … Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid].

  6. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.

  7. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.

  8. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    Bufexamac was also withdrawn by the EMA in April 2010. … Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticSynonyms: 4-Butoxy-N-hydroxybenzeneacetamide
  9. Drug

    Urokinase

    go.drugbank.com/drugs/DB00013
    ApprovedInvestigationalWithdrawn

    [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138] … Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.

  10. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.